Nuromark-NT Tablet SR is a sustained-release formulation combining Pregabalin 75 mg and Nortriptyline 10 mg, designed for the management of neuropathic pain and related conditions. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channels to reduce neurotransmitter release, thereby alleviating neuropathic pain symptoms such as burning, shooting, or stabbing sensations. Nortriptyline, a tricyclic antidepressant, enhances noradrenergic and serotonergic neurotransmission by inhibiting the reuptake of norepinephrine and serotonin, contributing to pain relief and improving mood disturbances often associated with chronic pain. The sustained-release mechanism ensures a steady plasma concentration, improving patient compliance and minimizing peak-related adverse effects. Nuromark-NT is indicated for peripheral and central neuropathic pain, diabetic neuropathy, postherpetic neuralgia, and other chronic pain syndromes where combination therapy is warranted. It should be used under medical supervision, with dose adjustments based on clinical response and tolerability. Common side effects may include dizziness, somnolence, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with renal impairment, cardiovascular disease, or a history of seizures. Nuromark-NT Tablet SR offers a synergistic approach to neuropathic pain management, combining analgesic and antidepressant properties in a convenient dosing regimen.